ArticleCureus2026
Combined Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) and Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) Therapy to Restore Fertility in Patients With Obesity, Polycystic Ovary Syndrome, and Incident Type 2 Diabetes.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Benefits of Incretin Therapy on Ovarian Function: A Scientific Literature Review.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and type 2 diabetes (T2D) frequently complicate polycystic ovary syndrome (PCOS), exacerbating subfertility. We report two cases of obese women with newly diagnosed T2D and PCOS-related subfertility successfully treated with a combination of a glucagon-like peptide-1 receptor agonist (GLP-1RA) and a sodium-glucose co-transporter 2 inhibitor (SGLT2i). Both patients achieved rapid, substantial weight loss (23% and 10.2%, respectively), leading to menstrual normalization and accidental spontaneous conception within seven months. Medications were discontinued upon confirmation of pregnancy. Both pregnancies were uncomplicated, resulting in healthy live births. Early combination therapy with GLP-1RA and SGLT2i may offer a potent approach to expedite spontaneous conception in this high-risk population. While inadvertent early pregnancy exposure shows no major teratogenic concern based on emerging preliminary studies, immediate discontinuation with transitioning to metformin and/or insulin prior to planning pregnancy remains the clinical standard until robust safety profiles regarding embryotoxicity are established.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.